Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same

a vaccine composition and composition technology, applied in the field of inactivated feline chlamydia vaccine composition, can solve the problems of fpn being a major problem, inability to detect chlamydia, and inability to detect chlamydia, and achieve the effect of high antigen load

Inactive Publication Date: 2003-09-11
AMERICAN HOME PRODUCTS CORPORATION
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] It is an object of the present invention to provide an inactivated feline chlamydia vaccine composition having high antigen load in combination with a potent adjuvant which will elicit corresponding antisera when administered systemically to a subject feline.
[0011] It is a further object of the present invention to provide a method for preventing chlamydia infection in felines by immunizing these animals with an efficacious inactivated vaccine composition.
[0039] The immunogenically stimulating adjuvants augment the immune response provoked by the inactivated chlamydia cells. The inactivated chlamydia cells may or may not elicit a desired immune response, e.g., a local mucosal and / or a strong systemic immunity, when systemically administered alone. An essential feature of the present invention is the combination of the inactivated chlamydia cells and immunogenically stimulating adjuvant, which provide the desired immune response.
[0048] It is advantageous to formulate the vaccine composition of this invention in a dosage unit form to facilitate administration and insure uniformity. Thus, in another embodiment, this vaccine composition can be formulated in dosage unit form comprising at least about 2.times.10.sup.4 inactivated chlamydia cells, preferably at least about 1.times.10.sup.5 cells.

Problems solved by technology

All age groups of cats are susceptible and although mortality is not great, infected kittens and older animals may become severely debilitated.
Furthermore, because of its extreme communicability, FPn constitutes a major problem in pet hospitals, clinics and catteries, etc.
Persistent genital tract infection by C. psittaci is believed to be a cause of reproductive failure in catteries, however the mechanism of such failure is unclear.
Vaccination studies with modified-live compositions has produced conflicting results.
The induced protection was comparable to that of modified-live vaccines similarly purified, but was inferior to a modified-live crude yolk sac preparation.
Moreover, prior inactivated preparations have been unsuccessful or markedly inferior to modified-live preparations.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
  • Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
  • Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same

Examples

Experimental program
Comparison scheme
Effect test

example 2

[0061] Challenge and Isolation of C. psittaci in Felines

[0062] Two challenge preparations were evaluated in young cats in order to produce consistent disease due to infection with Chlamydia psittaci.

[0063] A. Experimental Animals

[0064] Ten animals used for this experiment were specific pathogen free (SPF) cats purchased from Liberty Laboratories (Liberty Corner, N.J.). The cats were screened after receipt of antibodies to C. psittaci utilizing an ELISA assay for C. psittaci antibodies. The SPF cats were 10 to 12 weeks of age at the time of vaccination and approximately 16 to 18 weeks old at the time of challenge.

[0065] B. Experimental Design

[0066] Two 1 mL vaccinations of the FCP 1 and FCP 2 vaccines or fractional dose vaccines were administered intramuscularly 21 days apart. Two doses of Solvay's modified-live Eclipse.RTM.4 vaccine were given 21 days apart according to the label directions. Animals receiving the modified live vaccine were held in separate facilities both before and...

example 3

[0089] Correlation of Immunogenicity and Potency of FCP Vaccines Containing Saponin / AlPO.sub.4 as Adjuvants

[0090] A total of 91 SPF cats, 10 to 12 weeks of age, were utilized in this study. The FCP 1A vaccination group consisted of 21 cats. The FCP 1B and FCP 2A vaccination groups consisted of 20 cats each. The FCP 2B and the Solvay Eclipse.RTM.4 vaccination groups included 11 cats each. The non-vaccinated control group consisted of 11 cats. The reagent used to challenge the cats in the immunogenicity trials was a combination of the NVSL challenge preparation and the low egg passage preparation diluted to 10.sup.5.79 FLD.sub.50 titer per cat. Results indicate a reliable and accurate reproduction of disease from the use of the combined low egg passage preparation and NVSL challenge preparation.

[0091] A. Reduction in Fever in Vaccinated Cats as Compared to Controls Following Challenge

[0092] The temperature response of each animal in the five vaccine and control groups were measured. T...

example 4

[0104] Post Challenge Evaluation of Felines Vaccinated with FCP Compositions Containing EMA / NEOCRYL.RTM. / MVP Adjuvant System

[0105] The efficacy of FCP vaccines containing EMA / Neocryl.RTM. / MVP as adjuvants was evaluated in young cats via vaccination and challenge studies. The vaccines were administered intramuscularly or subcutaneously in two doses, 21 days apart. Efficacy of the FCP vaccines was demonstrated by challenging the vaccinated groups and age-match controls with the low egg passage virulent pneumonitis preparation as described below.

[0106] A total of 100 healthy, specific pathogen free (SPF) cats were purchased for the FCP vaccine efficacy testing. Ninety-five (95) cats were purchased from Liberty Laboratories (Liberty Crossing, N.J.) and five (5) cats were acquired from Harlan-Spraque Dawley (Indianapolis, Ind.). All test animals were approximately 16 to 20 weeks of age at the time of vaccination and approximately 20 to 25 weeks of age at the time of challenge. These anim...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
volumeaaaaaaaaaa
volumesaaaaaaaaaa
Login to view more

Abstract

This invention provides a feline vaccine composition comprising an immunogenically active component having inactivated mammalian chlamydial cells or antigens derived therefrom, in combination with an effective amount of an immunogencally suitable adjuvant; and a veterinary pharmaceutically acceptable carrier or diluent. The vaccine composition is useful to prevent chlamydia, e.g. C. psittaci, infections or diseases in felines, and may also be combined with other vaccine compositions or therapy. A process for producing C. psittaci suitable for use in the production of safe and effective chlamydia vaccines, and a method for preventing chlamydia infections or diseases in felines, are also provided.

Description

[0001] This application is a continuation of application Ser. No. 08 / 467,775, filed Jun. 6, 1995 (now U.S. Pat. No. 6,004,563); which was a continuation of Ser. No. 08 / 065,741, filed May 20, 1993, which was a divisional of Ser. No. 07 / 610,229, filed Nov. 7, 1990 (now U.S. Pat. No. 5,242,686, issued Sep. 7, 1993). Each of these prior applications is hereby incorporated herein by reference, in its entirety.[0002] The present invention relates to vaccines for veterinary use. In particular, the invention relates to vaccines comprising a combination of one or more immunologically active components, i.e. inactivated Chlamydia psittaci or antigens derived therefrom, for prevention and treatment of chlamydia diseases in mammals, such as cats. The invention also relates to methods for immunizing and treating such animals with such vaccines.[0003] Feline Chlamydia psittaci is the etiologic agent for a common conjunctual and respiratory disease of cats known as feline pneumonitis (FPn) (Baker,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/118
CPCA61K39/118
Inventor CHU, HSIEN-JUECHAVEZ, LLOYDACREE, WILLIAM M.CHANG, LUCILLE W.S.
Owner AMERICAN HOME PRODUCTS CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap